glp-1 side Effect Relief Hair Loss May Be a

Topline The use of GLP-1 medications like semaglutide for weight loss has increased twofold over the past decade, but declined in use among those with type 2 diabetes, according to a new study, and the researchers warn the resulting and ongoing drug shortage may limit the access people with diabetes have to the drugs

Consequently, companies such as Novo Nordisk and Eli Lilly are investing heavily in next-generation formulations, including oral small-molecule GLP-1 receptor agonists such as orforglipron, which aim to expand patient accessibility and therapeutic scope The demand for GLP-1 drugs that address a wider array of metabolic conditions is growing rapidly across global markets, as patients and healthcare providers increasingly seek holistic and effective long-term treatment options for obesity and its comorbidities GLP-1 Receptor Agonists Obesity Drugs Market Dynamics Driver Surging Demand Due to Rising Obesity Prevalence and Enhanced Clinical Outcomes The global surge in obesity rates and associated comorbidities such as type 2 diabetes and cardiovascular diseases is significantly driving demand for GLP-1 receptor agonist drugs as effective medical weight loss therapies For instance, in May 2024, Novo Nordisk announced a USD 4.1 billion expansion in its U.S

However, experts caution that price drops may not happen instantly

Why your pineal gland matters more than you think Rene Descartes called it the seat of the soul

Non-diabetic patients show comparable weight loss trajectories to diabetic patients in clinical trials when baseline characteristics are similar